Medical device manufacturer Stimwave Technologies has started a multi-centre, randomised, double-blind and placebo-controlled clinical trial of its wireless high frequency stimulator to treat chronic and non-specific origin lower back pain.

The trial, called the Tsunami study will compare a sham device to stimulation of spinal nerves at settings not perceived by the patient, allowing for a genuine, blinded patient experience.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In 2015, 45 patients will be enrolled in the trial at centres throughout the UK, Netherlands, Switzerland and Belgium.

Stimwave Technologies said the trial unbinds patients after 90 days, after which time the sham group devices are enabled to allow participants to benefit from long-term therapy.

The trial’s primary endpoints are overall pain scores using visual analog score (VAS) measurements, while secondary endpoints include quality of life (QoL), patients global impression of change (PGIC) and reduction in the use of opioids.

See Also:

"In 2015, 45 patients will be enrolled in the trial at centres throughout the UK, Netherlands, Switzerland and Belgium."

Stimwave Technologies chairman Laura Tyler Perryman said: "The unique Stimwave technology platform allows, for the first time, a true scientific study of neuromodulation therapy that can have no observational bias, since all of the products are provided by the same manufacturer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"It is the hope that the outcome of the study will provide proper evidence-based research to encourage utilisation of electroceutical devices to replace or reduce dependence on pain medications, and bring forth a new era in medicine with potentially fewer side effects than medications."

The Stimwave device is introduced through a needle procedure, reducing the need for complicated surgical intervention, as well as risks of infection and adverse events associated with implantable pulse generators.

Principal investigator of the trial Dr Adnan Al-Kaisy said: "The medical community at large has long awaited the ability to conduct placebo controlled randomised controlled trial (RCT) for the treatment of chronic axial lower back pain patients without prior back surgery.

"This technology platform allows for flexibility in treatment to conduct this research that will benefit the field of neuromodulation immensely."